Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    51,230.79
    +519.87 (+1.03%)
     

  • CMC Crypto 200

    1,339.33
    +62.36 (+4.89%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
BRANDS:

Meet one of the UK’s largest unknown start-ups

Video editing platform Veed has grown to 10 million users

Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

For the quarter ended March 2024, Labcorp (LH) reported revenue of $3.18 billion, down 15.9% over the same period last year. EPS came in at $3.68, compared to $3.82 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.13 billion, representing a surprise of +1.59%. The company delivered an EPS surprise of +6.36%, with the consensus EPS estimate being $3.46.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Labcorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Biopharma Laboratory Services: $710.90 million versus $697.35 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -49.3% change.

  • Revenues- Diagnostics Laboratories: $2.48 billion compared to the $2.42 billion average estimate based on three analysts. The reported number represents a change of +4.1% year over year.

  • Adjusted Operating Income- Biopharma Laboratory Services: $99.90 million compared to the $92.47 million average estimate based on three analysts.

  • Adjusted Operating Income- Diagnostics Laboratories: $417.90 million versus $427.90 million estimated by three analysts on average.

View all Key Company Metrics for Labcorp here>>>

Shares of Labcorp have returned -4% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Labcorp (LH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research